Navigation Links
New ISHLT cardiac allograft vasculopathy standardized nomenclature
Date:6/24/2010

New York, New York, June 25, 2010 Cardiac allograft vasculopathy (CAV), the major limitation to long term survival after heart transplantation, occurs when blood vessels in a transplanted heart progressively narrow and lead to dysfunction of the heart muscle or sudden death. Ascertaining benefit from appropriate treatment for this condition has been hampered in part because of the lack of a standard nomenclature. In an article published online today in The Journal of Heart and Lung Transplantation (www.jhltonline.org), clinicians representing the International Society for Heart and Lung Transplantation (ISHLT) Working Group on Classification of Cardiac Allograft Vasculopathy issued the first international consensus formulation of a standardized nomenclature for CAV.

"The development of cardiac allograft vasculopathy remains the Achilles heel of cardiac transplantation," commented working group leader, Mandeep R. Mehra, MD, Herbert Berger Professor and Head of Cardiology, University of Maryland School of Medicine, Baltimore, MD. "Unfortunately, the definitions of cardiac allograft vasculopathy are diverse and confusion abounds. There have been no uniform international standards for the nomenclature of this entity. The lack of a standard language has led to confusion in the interpretation of various studies and several unanswered questions persist. The ISHLT consensus statement is the first step in resolving these issues and improving cardiac transplant patient outcomes."

This consensus document, commissioned by the International Society for Heart and Lung Transplantation Board, is based on best evidence and clinical consensus derived from critical analysis of available information pertaining to angiography, intravascular ultrasound imaging, microvascular function, cardiac allograft histology, circulating immune markers, noninvasive imaging tests, and gene-based and protein-based biomarkers.

ISHLT President, John Dark, FRCS, stated, "The consensus document from the international working group led by Dr. Mehra defines the descriptors of the major clinical challenge late after cardiac transplantation. It also defines the ISHLT as the organization unifying all those, scientists and clinicians, working in this field, and able to put the stamp of authority on the recommendations. The topic is rapidly evolving, but Dr Mehra and his colleagues have undertaken to keep the data under close review. We can anticipate further definitive analyses in the future."

This article presents 5 consensus statements that describe how to best identify CAV and assess its severity. By developing a standard nomenclature, appropriate treatment options can be selected, depending on the level of CAV. Four levels of CAV are defined, ranging from CAV0 (not significant), where no angiographic lesions are detected, to CAV3 (severe), where multiple major heart vessels are involved. Key among the recommendations to define the severity of CAV is to view the anatomy of the allograft vasculature in concert with the physiological effects of the disease on cardiac allograft function.


'/>"/>

Contact: Linda Gruner
jhltmedia@elsevier.com
212-633-3923
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. Cardiac MRI in the ER cuts costs, hospital admissions for chest pain patients
2. Traditional neurologic exams inadequate for predicting survival of cardiac arrest patients
3. Mediterranean Diet Linked to Better Cardiac Function
4. Surviving Cardiac Arrest Depends on Your Location
5. Chances of surviving cardiac arrest depends on your neighborhood
6. Nurse/tech symposium at TCT 2010 will address complex issues in the cardiac cath lab
7. Concerns over radiation exposure may overshadow life-saving benefits of cardiac imaging tests
8. Elsevier introduces Cardiac Electrophysiology Clinics
9. Noncardiac Chest Pain May Warrant More Management: Study
10. Coronary CTA a cost-effective alternative to cardiac catheterization for the evaluation of CAD
11. Outcomes of patients dismissed from the hospital with non-cardiac chest pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters of Science ... evaluation leaders with decades of experience who remain current practitioners in the field. ... system, there is a renewed demand for versatile, data-driven leadership.The American University’s MS ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement is a ... method is paramount to success. Selecting an inappropriate measurement method can cause costly ... use the same equipment. Rare or expensive substances are wasted and production may ...
(Date:1/23/2017)... ... January 23, 2017 , ... Gynecology Associates of ... gynecological services for women of all ages. The staff of Gynecology ... of reproductive services from routine health screenings to diagnosing and treating female concerns ...
(Date:1/23/2017)... ... ... “Some Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the ... of published author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He ... nineteen, a pastor for over fifteen years. He is a graduate of N.C. College ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals and ... a simple test will take days to arrive to the end customer, having to ... access to their lab tests, bypassing the cost and delay of traditional means. Now ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Jan 23, 2017 Research and Markets has announced ... Trends - Product - Forecast to 2025" report to their offering. ... Report Highlights: ... market trends to identify the investment opportunities Market forecasts ... Key market trends across the business segments, Regions and Countries ...
(Date:1/23/2017)... Jan. 23, 2017  Using Astute Medical,s ... risk for acute kidney injury (AKI) after open-heart ... care guidelines significantly improved outcomes by ... more than 33 percent, according to a ... Intensive Care Medicine. Experience ...
(Date:1/23/2017)... January 23, 2017 Ahead of today,s trading ... how they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... were relative laggards on Friday, January 20 th , 2017, down ... research reports on these stocks now at: ...
Breaking Medicine Technology: